Monitor the first day of trading under SLBT for price discovery and volume. Watch for subsequent disclosures on cash position, redemptions, and clinical trial timelines. The high implied valuation relative to the small PIPE and pre-revenue stage suggests significant speculative risk.
Price Chart
Executive Summary
SL Science Holding Ltd (SLBT) announced the closing of its business combination with SPAC Horizon Space Acquisition II Corp., with an implied equity valuation of approximately $5.568 billion and a concurrent $7.8 million PIPE financing. The combined company's ordinary shares are expected to begin trading on the Nasdaq Global Market under the ticker SLBT on June 15, 2026. The transaction provides capital to advance the company's preclinical Gamma delta T cell therapies for solid tumors, but no revenue or clinical data were disclosed.
Key Facts
- Business combination closed between SL BIO Ltd. and Horizon Space Acquisition II Corp. (HSPT).
- Implied equity valuation of SL Bio approximately $5.568 billion.
- Concurrent PIPE financing of $7.8 million closed.
- Ordinary shares of SL Science Holding Limited to trade on Nasdaq under ticker SLBT starting June 15, 2026.
- Company focuses on Gamma delta T cell 'off-the-shelf' therapies for solid tumors (pancreatic, brain cancers).
- Leadership team includes CEO William Wang, CFO Ray Leung, and independent directors with accounting and investment banking backgrounds.
Financial Impact
Implied equity valuation of approximately $5.568 billion; PIPE financing of $7.8 million. No revenue or earnings data provided.
Risk Factors
- Pre-revenue, preclinical-stage biotech with no approved products or clinical data.
- Implied valuation of $5.568 billion is extremely high for a pre-clinical company, increasing downside risk.
- Small $7.8 million PIPE may not provide sufficient capital runway for planned trials.
- Forward-looking statements about scalability and commercialization are unproven.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-073797 |
| Document: tm2617928d1_6k.htm | 0001104659-26-073797 |
| Document: 0001104659-26-073797-index-headers.html | 0001104659-26-073797 |
| Document: 0001104659-26-073797-index.html | 0001104659-26-073797 |
| Document: 0001104659-26-073797.txt | 0001104659-26-073797 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 26, 2026 1d ago | Press Release | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 1, 2026 26d ago | SC 13D/A | $1.57 | awaiting T+20 | — | $1.23 (−21.66%) |
Aug 13, 2026 10w ago | EFFECT | $2.71 $2.06 | ▼ −23.99% | ▼ −22.24% | $1.23 (−54.61%) |
Jul 31, 2026 12w ago | F-1 | $3.29 $2.73 | ▼ −17.02% | ▼ −18.26% | $1.23 (−62.61%) |
Jul 10, 2026 15w ago | 6-K | $4.73 $2.67 | ▼ −43.55% | ▼ −45.98% | $1.23 (−74.00%) |
Jun 18, 2026 18w ago | 20-F | $4.52 $4.30 | ▼ −4.87% | ▼ −4.72% | $1.23 (−72.79%) |
Jun 17, 2026 18w ago | 3 | $6.38 $4.33 | ▼ −32.13% | ▼ −33.45% | $1.23 (−80.72%) |
Jun 15, 2026 19w ago | 3 | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
Jun 15, 2026 19w ago | 6-K | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers